PL1756064T3 - Pochodne pirazolu, kompozycje zawierające takie związki oraz sposoby ich zastosowania - Google Patents

Pochodne pirazolu, kompozycje zawierające takie związki oraz sposoby ich zastosowania

Info

Publication number
PL1756064T3
PL1756064T3 PL05754758T PL05754758T PL1756064T3 PL 1756064 T3 PL1756064 T3 PL 1756064T3 PL 05754758 T PL05754758 T PL 05754758T PL 05754758 T PL05754758 T PL 05754758T PL 1756064 T3 PL1756064 T3 PL 1756064T3
Authority
PL
Poland
Prior art keywords
compounds
methods
compositions containing
pyrazole derivatives
pyrazole
Prior art date
Application number
PL05754758T
Other languages
English (en)
Inventor
Emma R Parmee
Yusheng Xiong
Jian Guo
Rui Liang
Linda Brockunier
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of PL1756064T3 publication Critical patent/PL1756064T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL05754758T 2004-06-04 2005-05-31 Pochodne pirazolu, kompozycje zawierające takie związki oraz sposoby ich zastosowania PL1756064T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57711604P 2004-06-04 2004-06-04
PCT/US2005/018828 WO2005121097A2 (en) 2004-06-04 2005-05-31 Pyrazole derivatives, compositions containing such compounds and methods of use
EP05754758A EP1756064B1 (en) 2004-06-04 2005-05-31 Pyrazole derivatives, compositions containing such compounds and methods of use

Publications (1)

Publication Number Publication Date
PL1756064T3 true PL1756064T3 (pl) 2008-11-28

Family

ID=35335786

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05754758T PL1756064T3 (pl) 2004-06-04 2005-05-31 Pochodne pirazolu, kompozycje zawierające takie związki oraz sposoby ich zastosowania

Country Status (34)

Country Link
US (2) US7598285B2 (pl)
EP (1) EP1756064B1 (pl)
JP (2) JP4108739B2 (pl)
CN (1) CN1964947A (pl)
AR (2) AR049291A1 (pl)
AT (1) ATE395338T1 (pl)
AU (2) AU2005252183B2 (pl)
BR (1) BRPI0511703B8 (pl)
CA (1) CA2566945C (pl)
CR (1) CR8766A (pl)
CY (1) CY1108544T1 (pl)
DE (1) DE602005006806D1 (pl)
DK (1) DK1756064T3 (pl)
EA (1) EA012431B1 (pl)
EC (1) ECSP067062A (pl)
ES (1) ES2306165T3 (pl)
GE (1) GEP20094605B (pl)
HR (1) HRP20080311T3 (pl)
IL (1) IL179754A (pl)
MA (1) MA28673B1 (pl)
MX (1) MXPA06014084A (pl)
MY (1) MY143599A (pl)
NI (1) NI200600290A (pl)
NO (1) NO339149B1 (pl)
NZ (1) NZ551405A (pl)
PE (1) PE20060427A1 (pl)
PL (1) PL1756064T3 (pl)
PT (1) PT1756064E (pl)
SI (1) SI1756064T1 (pl)
TN (1) TNSN06397A1 (pl)
TW (1) TWI293952B (pl)
UA (1) UA85884C2 (pl)
WO (1) WO2005121097A2 (pl)
ZA (1) ZA200609489B (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004030318D1 (de) 2003-01-27 2011-01-13 Merck Sharp & Dohme Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren
ATE395338T1 (de) 2004-06-04 2008-05-15 Merck & Co Inc Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren
EP1773330B1 (en) * 2004-07-22 2010-05-26 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
AU2006276072A1 (en) 2005-07-26 2007-02-08 Merck Sharp & Dohme Corp. Process for synthesizing a substituted pyrazole
AR056574A1 (es) * 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
EP2114891A1 (en) * 2007-01-17 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. Substituted pyrazoline compounds with acat inhibition activity
PT2129654E (pt) 2007-02-09 2014-09-04 Metabasis Therapeutics Inc Antagonistas do receptor de glucagina
WO2009005675A1 (en) * 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
WO2009035558A1 (en) * 2007-09-12 2009-03-19 Merck & Co., Inc. Process for the production of a crystalline glucagon receptor antagonist compound
NZ588011A (en) * 2008-03-05 2012-06-29 Takeda Pharmaceutical Heterocyclic compounds having glucagon antagonistic action useful for treating diabetes
CN102083467B (zh) 2008-03-11 2013-12-25 Aska制药株式会社 固体分散体及其药物组合物、以及它们的制备方法
JP2011520897A (ja) 2008-05-16 2011-07-21 シェーリング コーポレイション グルカゴン受容体アンタゴニスト、組成物およびそれらの使用方法
MX2011001708A (es) 2008-08-13 2011-04-26 Metabasis Therapeutics Inc Antagonistas de glucagon.
RU2008135294A (ru) * 2008-08-29 2010-03-10 Дик Корпорейшн (Jp) Нафталиновые производные
EP2346830B1 (en) * 2008-09-15 2015-05-13 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010039789A1 (en) * 2008-10-03 2010-04-08 Schering Corporation Spiro-imidazolone derivatives as glucagon receptor antagonists
WO2010093535A1 (en) 2009-02-12 2010-08-19 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8318667B2 (en) 2009-02-25 2012-11-27 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8470773B2 (en) 2009-06-12 2013-06-25 Merck Sharp & Dohme Corp. Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
WO2011037815A1 (en) 2009-09-22 2011-03-31 Schering Corporation Novel pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
WO2012085745A1 (en) 2010-12-23 2012-06-28 Pfizer Inc. Glucagon receptor modulators
PT2673260T (pt) 2011-02-08 2016-10-24 Pfizer Modulador do recetor de glucagon
JP5647379B2 (ja) 2011-07-22 2014-12-24 ファイザー・インク キノリニルグルカゴン受容体モジュレーター
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CN103933032B (zh) * 2013-12-30 2019-08-23 北京赛林泰医药技术有限公司 作为抗癌药物的吡唑类衍生物的使用方法和用途
JP2017519000A (ja) 2014-06-12 2017-07-13 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴンアンタゴニスト
KR102708864B1 (ko) 2016-08-30 2024-09-25 리제너론 파마슈티칼스 인코포레이티드 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법
TWI763705B (zh) * 2016-09-06 2022-05-11 比利時商健生藥品公司 可作為升糖素受體拮抗劑之吲哚衍生物
US20190248888A1 (en) 2016-10-20 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
JP7781519B2 (ja) 2017-08-22 2025-12-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法
JP2021513564A (ja) 2018-02-13 2021-05-27 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体拮抗薬

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9303993D0 (en) * 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
EP0859771A4 (en) 1995-10-31 2000-03-15 Merck & Co Inc SUBSTITUTED PYRIDYLPYRROLE, PREPARATIONS CONTAINING SUCH COMPOUNDS AND METHOD FOR THE USE THEREOF
AR008789A1 (es) * 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5776954A (en) * 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
EP0959885A4 (en) 1996-11-20 2002-07-17 Merck & Co Inc TRIARYL SUBSTITUTED IMIDAZOLES AND METHODS OF USE
JP2001504490A (ja) 1996-11-20 2001-04-03 メルク エンド カンパニー インコーポレーテッド トリアリール置換イミダゾール、そのような化合物を含む組成物及び使用方法
EP0959886A4 (en) 1996-11-20 2001-05-02 Merck & Co Inc TRIARYL SUBSTITUTED IMIDAZOLES AS GLUCAGON ANTAGONISTS
WO1998025907A1 (en) * 1996-12-12 1998-06-18 Banyu Pharmaceutical Co., Ltd. Pyrazole derivatives
WO1998047509A1 (en) 1997-04-18 1998-10-29 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6420427B1 (en) * 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
EP1042293B9 (en) 1997-12-19 2008-09-03 Amgen Inc. Substituted pyridine and pyridazine compounds and their pharmaceutical use
CZ2001965A3 (cs) 1998-09-17 2002-02-13 Bristol-Myers Squibb Company Lék pro oąetřování atherosklerózy nebo diabetes typu II, farmaceutická kombinace a její pouľití
US6503949B1 (en) * 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
KR100730019B1 (ko) * 1999-08-10 2007-06-20 바이엘 크롭사이언스 케이. 케이. 제초성 테트라졸리논 유도체
PL356487A1 (pl) * 1999-11-10 2004-06-28 Takeda Chemical Industries, Ltd. Zawierające azot 5-członowe związki heterocykliczne
US6562807B2 (en) * 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
CA2415742A1 (en) * 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
WO2002040444A1 (en) 2000-11-17 2002-05-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
ITMI20010733A1 (it) * 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
US6881746B2 (en) * 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
US6762318B2 (en) * 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
WO2003051357A1 (en) 2001-12-19 2003-06-26 Novo Nordisk A/S Glucagon receptor antagonists/inverse agonists
AU2002347022A1 (en) 2001-12-20 2003-07-09 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
WO2003064404A1 (en) * 2002-02-01 2003-08-07 Dainippon Pharmaceutical Co., Ltd. 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
WO2004009158A2 (en) 2002-07-19 2004-01-29 Baxter International Inc. Systems and methods for performing peritoneal dialysis
EP1400243A1 (en) 2002-09-19 2004-03-24 Tanabe Seiyaku Co., Ltd. Calcium-activated K channel activator
US20060116366A1 (en) * 2002-12-04 2006-06-01 Parmee Emma R Spirocyclic ureas, compositions containing such compounds and methods of use
DE602004030318D1 (de) * 2003-01-27 2011-01-13 Merck Sharp & Dohme Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren
EP1633354B1 (en) * 2003-04-14 2008-01-23 The Institutes for Pharmaceutical Discovery, LLC N-(((((1,3-thiazol-2-yl)amino)carbonyl)phenyl)sulfonyl)phenylalanine derivatives and related compounds for the treatment of diabetes
EP1626717A4 (en) * 2003-05-09 2009-09-09 Merck & Co Inc BENZIMIDAZOLE, COMPOSITIONS AND METHOD OF ADMINISTRATION CONTAINING SUCH COMPOUNDS
ATE395338T1 (de) * 2004-06-04 2008-05-15 Merck & Co Inc Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren
EP1773330B1 (en) * 2004-07-22 2010-05-26 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
AR056574A1 (es) * 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso

Also Published As

Publication number Publication date
JP2008150388A (ja) 2008-07-03
JP2008505062A (ja) 2008-02-21
JP4108739B2 (ja) 2008-06-25
EP1756064B1 (en) 2008-05-14
EP1756064A2 (en) 2007-02-28
EA012431B1 (ru) 2009-10-30
AU2008229701A1 (en) 2008-10-30
AU2008229701B2 (en) 2010-03-04
AR088919A2 (es) 2014-07-16
NI200600290A (es) 2007-08-07
AU2005252183B2 (en) 2008-07-17
US20090176854A1 (en) 2009-07-09
ZA200609489B (en) 2007-10-31
ES2306165T3 (es) 2008-11-01
AR049291A1 (es) 2006-07-12
EA200602196A1 (ru) 2007-06-29
US20050272794A1 (en) 2005-12-08
US7598285B2 (en) 2009-10-06
UA85884C2 (uk) 2009-03-10
MA28673B1 (fr) 2007-06-01
AU2008229701C1 (en) 2010-07-29
ECSP067062A (es) 2007-01-26
NO339149B1 (no) 2016-11-14
BRPI0511703A (pt) 2008-01-08
AU2005252183A1 (en) 2005-12-22
MXPA06014084A (es) 2007-02-15
US7799818B2 (en) 2010-09-21
SI1756064T1 (sl) 2008-12-31
WO2005121097A3 (en) 2006-02-16
BRPI0511703B8 (pt) 2021-05-25
GEP20094605B (en) 2009-02-10
IL179754A0 (en) 2007-05-15
JP4733153B2 (ja) 2011-07-27
CA2566945C (en) 2010-09-21
IL179754A (en) 2013-12-31
CN1964947A (zh) 2007-05-16
HRP20080311T3 (hr) 2008-07-31
TW200604179A (en) 2006-02-01
CR8766A (es) 2007-08-28
DK1756064T3 (da) 2008-09-22
NO20070073L (no) 2007-03-05
MY143599A (en) 2011-06-15
CY1108544T1 (el) 2014-04-09
CA2566945A1 (en) 2005-12-22
TNSN06397A1 (en) 2008-02-22
PT1756064E (pt) 2008-07-22
BRPI0511703B1 (pt) 2018-07-17
DE602005006806D1 (de) 2008-06-26
WO2005121097A2 (en) 2005-12-22
NZ551405A (en) 2009-06-26
TWI293952B (en) 2008-03-01
ATE395338T1 (de) 2008-05-15
PE20060427A1 (es) 2006-06-19

Similar Documents

Publication Publication Date Title
IL179754A0 (en) Pyrazole derivatives, compositions containing such compounds and methods of use
IL190477A0 (en) Pyrazole derivatives, compositions containing such compounds and methods of use
IL176571A0 (en) Substituted azole derivatives, compositions, and methods of use
IL179595A0 (en) Substituted indazoles, compositions containing same, preparation and use
IL179757A0 (en) Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof
IL173044A0 (en) Aryl and heteroaryl compounds, compositions, and methods of use
IL179613A0 (en) Compounds and compositions as protein kinase inhibitors
PL1713806T3 (pl) Związki i kompozycje jako inhibitory kinaz białkowych
IL182687A0 (en) Compounds and compositions as protein kinase inhibitors
IL178297A0 (en) Hydrazide derivatives and pharmaceutical compositions containing the same
EP1673343A4 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
EP1670771A4 (en) COMPOUNDS AND COMPOSITIONS INHIBITING PROTEIN-KINASES
IL182664A0 (en) Triazole derivatives and pharmaceutical compositions containing the same
IL182126A (en) Preparations containing and used in the history of 5-phenoxyalkoxypsoralen
IL181683A0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
IL179496A0 (en) Triazole derivatives and pharmaceutical compositions containing the same
IL177260A0 (en) Indazole derivatives and pharmaceutical compositions containing them
EP1658290A4 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
IL198328A0 (en) Substituted pyrazoles, compositions containing these, method of production and use
IL177496A0 (en) Amido-substituted hydroxy -6-phenylphenanthridine derivatives and pharmaceutical compositions containing the same
EP1735282A4 (en) PYRAZOLE COMPOUNDS AND USES
EP1765820A4 (en) COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEIN KINASES
ZA200703130B (en) Compounds and compositions as protein kinase inhibitors
EP1670780A4 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
IL179530A0 (en) Novel compounds, pharmaceutical compositions containing same and methods of use for same